Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Non-infectious Uveitis Affecting the Posterior Segment of the Eye · ANIP

ANI PHARMACEUTICALS

ANI Pharmaceuticals is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker ANIP. Primary therapeutic focus areas include Diabetic Macular Edema, Non-infectious Uveitis Affecting the Post

500 Alexander Park, Princeton, New Jersey 08540, US HQ
678 Employees
Public company Type
ANIP · NYSE Ticker
Company details
Status
Public
HQ
500 Alexander Park, Princeton, New Jersey 08540, US
Employees
678
Programs
11
Drugs
7
Patents
7
Clinical program

fluocinolone acetonide

Phase 3 · small molecule · Diabetic Macular Edema

fluocinolone acetonide for Diabetic Macular Edema is a Phase 3 program (small_molecule) at ANI PHARMACEUTICALS INC with 3 ClinicalTrials.gov record(s).

← All ANI PHARMACEUTICALS INC projects Phase 3 small molecule completed

Internal code C-01-05-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ANI PHARMACEUTICALS INC
Phase
Phase 3
Modality
small_molecule
Indication
Diabetic Macular Edema
Status
completed
Trials
3